Targeting of de novo purine synthesis can also be achieved through inhibition of one carbon folate pathway (54) or pyrimidine synthesis through inhibition of dihydroorotate dehydrogenase (DHODH) (55–57), which induces differentiation of AML cells. Here, DHODH is linked to acute myeloid leukemia.